about header
Press Releases
Print Text Size
  • 10/10/18 9:00 am EDT
    CAMBRIDGE, Mass.--

    Aubagio® (teriflunomide) significantly slowed whole brain volume loss (atrophy) compared with placebo in patients with a first clinical episode suggestive of multiple sclerosis (MS), according to new investigational data from a late-stage study. Additionally, in this study, the reduction of annual whole brain volume loss was associated with a delay in conversion to clinically definite MS.

    more...
  • 10/10/18 9:00 am EDT
    CAMBRIDGE, Mass.--

    Patients with relapsing remitting multiple sclerosis who received Sanofi’s Lemtrada® (alemtuzumab) continued to experience effects of treatment on disease activity through eight years, according to extension data of two Phase 3 studies. These results will be presented this week during the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Berlin, Germany.

    more...
  • 10/8/18 6:16 pm EDT
    CAMBRIDGE, MA--

    Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will present a diverse set of data from their joint clinical program investigating Libtayo® (cemiplimab-rwlc) at the ESMO 2018 Congress (European Society for Medical Oncology) from October 19 to 23 in Munich, Germany. These data span six different tumor types, including non-small cell lung cancer (NSCLC), cervical cancer, cutaneous squamous cell carcinoma (CSCC), hepatocellular carcinoma (HCC), head and neck squamous cell carcinoma (HNSCC) and basal cell carcinoma (BCC).

    more...
  • 10/8/18 2:33 pm EDT
    CAMBRIDGE, MA--

    Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that new investigational data on its marketed treatments for relapsing multiple sclerosis (MS), Lemtrada® (alemtuzumab) and Aubagio® (teriflunomide), will be presented during the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

    more...
  • 9/28/18 4:48 pm EDT
    PARIS AND TARRYTOWN, NY--

    The U.S. Food and Drug Administration (FDA) has approved Libtayo® (cemiplimab-rwlc) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. Libtayo is a fully-human monoclonal antibody targeting the immune checkpoint receptor PD-1 (programmed cell death protein-1) and is the first and only treatment specifically approved and available for advanced CSCC in the U.S.

    more...
  • 9/15/18 7:00 am EDT
    Paris and Tarrytown, NY--

    Detailed results from a pivotal Phase 3 trial showed Dupixent® (dupilumab) monotherapy demonstrated a significant improvement in signs and symptoms of atopic dermatitis and certain quality of life measures in adolescent patients (12-17 years) with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable. These data were presented today at the 27th European Academy of Dermatology and Venereology (EADV) Congress in Paris, France.

    more...
  • 9/3/18 7:56 am EDT
    Paris--

    The European Commission has granted marketing authorization for Cablivi™ (caplacizumab) for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood-clotting disorder. Cablivi is the first therapeutic specifically indicated for the treatment of aTTP.

    more...
  • 7/18/18 7:07 am EDT
    Cambridge, Mass. and Redwood City, CA--

    Sanofi and REVOLUTION Medicines, Inc. today announced an exclusive worldwide partnership to develop and commercialize targeted therapies, based on the biology of the cellular enzyme SHP2, for patients with non-small lung cancer and other types of cancer carrying certain mutations. This collaboration builds on precision oncology discoveries by REVOLUTION Medicines and preclinical development of RMC-4630, the company’s lead small molecule inhibitor of SHP2, and will apply Sanofi’s expertise in oncology research and drug development.

    more...
  • 6/4/18 2:20 pm EDT
    PARIS and TARRYTOWN, NY--

    The New England Journal of Medicine (NEJM) today published pivotal data from two trials evaluating cemiplimab in advanced cutaneous squamous cell carcinoma (CSCC). The results were also presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. Advanced CSCC, the deadliest nonmelanoma skin cancer, encompasses both patients with metastatic CSCC and those with locally advanced CSCC who are not candidates for surgery; there is currently no approved treatment for these patients.

    more...
  • 5/21/18 2:21 pm EDT
    PARIS and TARRYTOWN, NY--

    PARIS and TARRYTOWN, NY – May 21, 2018 –The New England Journal of Medicine (NEJM) today published detailed results from two Phase 3 trials for the investigational use of Dupixent® (dupilumab) in moderate-to-severe asthma. The results showed that Dupixent significantly reduced the risk of severe asthma attacks (exacerbations), improved lung function and reduced dependence on oral corticosteroids (OCS). The trials, known as QUEST and VENTURE, are part of the pivotal clinical trial program that evaluated Dupixent in uncontrolled asthma patients.

    more...
Contact Us
 

Media Resources

Tweets

Social Media

Business Wire NewsHQ℠
infoBox